基本信息
浏览量:3
职业迁徙
个人简介
Dr. Nahta's laboratory focuses on the biological and therapeutic implications of growth factor signaling crosstalk in breast cancer. Significant advances in the treatment of metastatic breast cancer include the development of therapies targeted against specific cancer-causing molecules. However, the success of these mono-targeted therapies is often limited by cross-talk between multiple signaling pathways. One molecule that is overexpressed in about 25% of metastatic breast cancers is the HER2/erbB2 oncogene. Approved treatments for HER2-overexpressing breast cancer include the HER2-targeted antibody trastuzumab and the dual EGFR/HER2 kinase inhibitor lapatinib. While both drugs successfully treat a percentage of HER2-overexpressing metastatic breast cancers, a significant number of patients show primary or acquired resistance to these treatments.
Dr. Nahta's laboratory is interested in understanding how cross-talk between HER2 and other growth factor signaling pathways affects the biology of HER2-overexpressing breast cancers, including how signaling cross-talk promotes resistance to trastuzumab and lapatinib. By understanding the basic signaling mechanisms contributing to therapeutic resistance, they can identify new molecular targets against which future drugs can be developed.
Dr. Nahta's laboratory is interested in understanding how cross-talk between HER2 and other growth factor signaling pathways affects the biology of HER2-overexpressing breast cancers, including how signaling cross-talk promotes resistance to trastuzumab and lapatinib. By understanding the basic signaling mechanisms contributing to therapeutic resistance, they can identify new molecular targets against which future drugs can be developed.
研究兴趣
论文共 57 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Yuhua Zhao,Hao Liu,Zixing Liu,Yan Ding, Susan P. LeDoux,Glenn L. Wilson, Richard Voellmy,Yifeng Lin,Wensheng Lin,Rita Nahta,Bolin Liu,Oystein Fodstad,
crossref(2023)
Yuhua Zhao,Hao Liu,Zixing Liu,Yan Ding, Susan P. LeDoux,Glenn L. Wilson, Richard Voellmy,Yifeng Lin,Wensheng Lin,Rita Nahta,Bolin Liu,Oystein Fodstad,
crossref(2023)
Jing Zhao,Jane Meisel,Yi Guo,Rita Nahta, Kung Lin Hsieh,Limin Peng,Zhimin Wei,Ruth O’Regan,Xiaoxian Li
E. Sanabria-Figueroa, S. M. Donnelly, K. C. Foy, M. C. Buss,R. C. Castellino,E. Paplomata,L. Taliaferro-Smith,P. T. P. Kaumaya,R. Nahta
MOLECULAR PHARMACOLOGYno. 6 (2020): 761-761
引用0浏览0引用
0
0
Resistance to Targeted Anti-Cancer TherapeuticsCurrent Applications for Overcoming Resistance to Targeted Therapiespp.191-221, (2019)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn